Blackstone Life Sciences startup Uniquity Bio emerged from stealth with an in-licensed drug candidate that could treat a wide range of immunology and inflammation indications. The antibody's target puts it in competition with drugs from AstraZeneca, Pfizer, and Sanofi.
COPD is the sixth leading cause of death—but more than 50% of those impacted don’t even have a diagnosis. The so-called silent epidemic demands urgent action, as exorbitant costs and preventable deaths skyrocket. This four-point plan outlines a holistic strategy to address COPD.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Starting July 1, Highmark Blue Cross Blue Shield Delaware members will be able to access Wellinks’ virtual services for Chronic Obstructive Pulmonary Disease (COPD). These services include pulmonary rehabilitation, coaching and tracking through connected devices and an app.
There is an urgent need to develop solutions that can enable the early diagnosis of COPD as any delays in the diagnosis of COPD represent a missed opportunity to slow disease progression through preventative interventions. Smoking cessation alone could save as many as 120,000 lives per year in the US alone.
Colder weather will always pose an additional risk to people with COPD, but this COPD season does not need to be so detrimental. To turn the tide, payers and providers must invest in preventive care to meet patients where they are before their conditions deteriorate.
it is imperative that rural healthcare organizations take steps now to ensure that they provide access to a specialist, through traditional or digital solutions to meet these patient’s critical needs.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
AireHealth, which makes portable nebulizers for patients with respiratory conditions, plans to launch its first connected product next year.
Kaia Health, a New York-based startup providing virtual care for COPD and musculoskeletal conditions, raised $26 million in series B funding.
David Van Sickle's eyes shine as he outlines the array of opportunities that have opened up ever since medical device maker ResMed acquired the Wisconsin startup in January 2019 for $225 million.
The FDA turned down the British drugmaker's approval application for PT010, which won approval in Japan a few months ago and is marketed there as Breztri Aerosphere. GlaxoSmithKline won approval for a three-drug COPD inhaler, Trelegy Ellipta, in 2017.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The research, which was published in the Journal of Telemedicine and Telecare, involved 39 patients who have COPD and had at least one hospitalization or emergency room visit during the year prior to enrollment.
Epharmix developed a unique, evidence-based tool to help both patients and clinicians.
Digital therapeutics company Propeller will continue to operate as a standalone business within ResMed's Respiratory Care portfolio.
In a phone interview, Propeller Health CEO David Van Sickle and CTO Greg Tracy discussed how their digital therapeutics company has evolved since its founding in 2010.
The San Francisco-based startup's platform aids care coordinators to assess and identify both clinical and sociodemographic risk factors for chronic illnesses like diabetes, COPD, chronic kidney disease, depression and congestive heart failure.